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Abstract: Here, we assessed whether 36 single nucleotide polymorphisms (SNPs) within the TNFSF4
and MAPKAPK2 loci influence the risk of developing invasive aspergillosis (IA). We conducted a two-
stage case control study including 911 high-risk patients diagnosed with hematological malignancies
that were ascertained through the aspBIOmics consortium. The meta-analysis of the discovery and
replication populations revealed that carriers of the TNFSF4rs7526628T/T genotype had a significantly
increased risk of developing IA (p = 0.00022). We also found that carriers of the TNFSF4rs7526628T
allele showed decreased serum levels of TNFSF14 protein (p = 0.0027), and that their macrophages
had a decreased fungicidal activity (p = 0.048). In addition, we observed that each copy of the
MAPKAPK2rs12137965G allele increased the risk of IA by 60% (p = 0.0017), whereas each copy of the
MAPKAPK2rs17013271T allele was estimated to decrease the risk of developing the disease (p = 0.0029).
Mechanistically, we found that carriers of the risk MAPKAPK2rs12137965G allele showed increased
numbers of CD38+IgM-IgD- plasmablasts in blood (p = 0.00086), whereas those harboring two copies
of the allele had decreased serum concentrations of thymic stromal lymphopoietin (p = 0.00097).
Finally, we also found that carriers of the protective MAPKAPK2rs17013271T allele had decreased
numbers of CD27-IgM-IgD- B cells (p = 0.00087) and significantly lower numbers of CD14+ and
CD14+CD16- cells (p = 0.00018 and 0.00023). Altogether, these results suggest a role of the TNFSF4
and MAPKAPK2 genes in determining IA risk.
Keywords: invasive aspergillosis; TNFSF4; MAPKAPK2; genetic susceptibility; B cells; monocytes;
serum biomarkers; TSLP; TNFSF14
1. Introduction
Invasive aspergillosis (IA) is the second-most common opportunistic mycosis, and fre-
quently affects allogenic stem cell and solid transplantation hosts [1], but also hematological
patients receiving myeloablative therapies and critically ill patients [2,3]. Epidemiological
studies have demonstrated that, despite the advent of new antifungal agents, IA inci-
dence remains unacceptably high and it is associated with poor prognosis [4]. Although
the molecular mechanisms underlying host defense against invasive fungal infections
have been extensively studied during recent years [5], the etiopathogenesis of this op-
portunistic infection is still poorly understood, which hampers the development of new
and effective therapeutic strategies. A large number of candidate gene association stud-
ies developed over the last decade have also shown that genetic determinants influence
both the susceptibility and outcome of the infection [6]. However, most of these studies
have been focused on pathogen-recognition receptors (PRRs) (PTX3, Dectin-1, Dectin-2,
DC-SIGN, TLRs, NOD, MelLec, MBL) [7–14], cytokines (IFNG, IL1 gene cluster, IL6, IL8,
IL10, IL12B) [15–17], chemokines (CXCL10) [18], and cell surface receptors (TNFR1, TNFR2,
CX3CR1) [19–23], whereas only a few studies have addressed the role of intracellular
signaling downstream of PRRs [22,24,25], effector T lineage factors, or master regulators of
cytokine biosynthesis [26].
Several investigations have demonstrated that TNFSF4 (also known as OX40L) expres-
sion is upregulated in Aspergillus fumigatus sensitized mice [27]. TNFSF4 mediates adhesion
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of activated T cells to endothelial cells during the infection, which is a key process to induce
the expression of leukocyte adhesion molecules (E-selectin, VCAM-1) and secretion of
proinflammatory cytokines [28]. In addition, it has been reported that, after activation by
thymic stromal lymphopoietin (TSLP), the ligation of TNFSF4 during the interaction of T
and dendritic cells (DCs) is a crucial process for clonal expansion of antigen-specific T-cells
and generation of memory T cells in response to A. fumigatus [29]. On the other hand,
it has been reported that MAPKAPK2, a downstream substrate of the p38MAPK (also
known as MK2), is a key factor in the modulation of cytokine production during infection
by phosphorylating and inactivating the mRNA-destabilizing and translation-inhibiting
protein tristetraprolin (TTP) [30]. In addition, it has been reported that MAPKAPK2 protein
is implicated in the modulation of LPS-induced macrophage activation and acute lung
injury by regulating let-7e miRNA [31] and likely by inhibiting TTP that controls the
posttranscriptional repression of cytokine biosynthesis in macrophages [32].
Considering the above-reported findings, we decided to investigate whether 36 sin-
gle nucleotide polymorphisms (SNPs) within the TNFSF4 and MAPKAPK2 loci could
influence the risk of developing IA by modulating immune responses and/or immune
cell populations. For that purpose, we conducted a two-stage candidate gene association
study including 991 hematological patients, of whom 164 were diagnosed with proven or
probable IA. In order to shed light into the molecular mechanisms underlying the most
interesting associations, we also investigated the role of the TNFSF4 and MAPKPAK2 vari-
ants in modulating immune responses against Aspergillus fumigatus conidia. Furthermore,
we evaluated whether TNFSF4 and MAPKPAK2 SNPs correlated with a panel of 103 sero-
logical and plasmatic inflammatory proteins, 7 serum steroid hormones, and counts of
91 blood-derived immune cell populations. Given the key role of macrophages in the host
defense against A. fumigatus, we also evaluated whether selected SNPs could correlate with
fungicidal activity of macrophages in an independent cohort of 108 healthy blood donors.
2. Methods
2.1. Discovery and Replication Populations
A total of 911 hematological patients at high risk of IA were included in this two-stage
case control study. All patients were allotransplanted or diagnosed with medullar aplasia,
acute myeloid leukemia, or acute lymphoid leukemia receiving intensive chemotherapy
regimens. The discovery population consisted of 423 European hematological patients,
67 diagnosed with proven or probable IA and 356 disease-matched patients without any
sign of infection and lacking pulmonary infiltrate for a period of, at least, 12 months.
Patients diagnosed with possible IA (unreliable diagnosis) were excluded from the study.
The replication population included 488 disease-matched patients, 97 of those diagnosed
with proven or probable IA. Both discovery and replication populations were ascertained
through the aspBIOmics consortium (www.aspbiomics.eu) that aims to identify and to
characterize new biomarkers for an effective management of IA using a broad range of
approaches including genetic association studies but also RNA, DNA, and proteome analy-
sis of A. fumigatus and multiple-ELISA assays and transcriptome analysis of immune cells
ex vivo. Demographic and clinical characteristics of the hematological patients included
in the discovery and replication cohorts have been reported in detail elsewhere [22,24,33].
The ethical committees of all participating centers and hospitals approved the study: Vir-
gen de las Nieves University hospital (0702/12, Granada, Spain), University Hospital
of Salamanca (NCT01742026, Salamanca, Spain), Clinic University Hospital of Valencia
(NCT01742026, Valencia, Spain), Centro Nacional de Microbiología (NCT01742026, Madrid,
Spain), University of Würzburg (173/11, Würzburg, Germany), Medical University of
Innsbruck (UN4529 and 04/2014, Innsbruck, Austria), Università Cattolica del S. Cuore
(0029458/16 and 0003932/17, Rome, Italy), and University of Modena and Reggio Emilia
(2629/16, Modena, Italy). Approval for the functional genomics studies was obtained from
the Arnhem-Nijmegen Ethical Committee (42561.091.12, Nijmegen, The Netherlands) and
from the Ethics Subcommittees for Life and Health Sciences of the University of Minho
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(SECVS, 014/2015, Braga, Portugal), and the National Commission for the Protection of
Data (1950/015, Braga, Portugal). In accordance with the Declaration of Helsinki, all par-
ticipants provided their written informed consent to participate in the study. Proven and
probable IA cases were diagnosed by experienced physicians and pathologists according to
the 2008 EORTC/MSG criteria [34] and all centers used galactomannan as microbiological
criteria for IA diagnosis.
2.2. DNA Extraction, SNP Selection, Genotyping, and Quality Control
Genomic DNA from hematological patients at high risk of IA was extracted from
saliva or blood samples using the Oragene®-DNA Self-Collection kit (Oragene) or the
QIAamp DNA Blood Mini kit (Valencia, CA, EEUU) according to manufacturer’s instruc-
tions. Common tagging SNPs (MAF > 5% and r2 ≥ 0.8) were selected for the MAPKAPK2
and TNFSF4 loci using Haploview according to the Gabriel et al. method [35]. Given
the large size of the TNFSF4 gene and the high number of tagging SNPs found, we
decided to select for genotyping only those tagging TNFSF4 SNPs with a predicted bi-
ological function according to the data publicly available in the integrated Regulome
database (www.regulomedb.org/), and eQTL browsers (www.gtexportal.org/home/ and
https://genenetwork.nl/bloodeqtlbrowser/). A total of 36 SNPs were selected for geno-
typing in the discovery and replication cohorts (Supplementary Table S1). Genotyping
of selected SNPs was performed using KASP® and Taqman® probes according to man-
ufacturer’s instructions (LGC Genomics, Hoddesdon, UK). For quality control, ~5% of
DNA samples were randomly included as duplicates and concordance between duplicate
samples was ≥99.0%.
2.3. Hardy–Weinberg Equilibrium, Genetic Association Analysis, and Meta-Analysis
Deviation from Hardy–Weinberg equilibrium (HWE) was tested in controls (non-IA
cases) by chi-square (χ2), and logistic regression adjusted for age, sex, and country of origin
was used to assess the associations of the TNFSF4 and MAPKAPK2 polymorphisms with
IA risk assuming log-additive, dominant, and recessive models of inheritance. Those SNPs
with the lowest p-value in the discovery population according to each genetic model were
advanced for replication and meta-analysis of the two populations using a fixed effect
model was performed to validate the association observed. Correction for multiple testing
was performed using the Bonferroni method but also considering the two inheritance
models tested (the log-additive/dominant that showed collinearity and the recessive
model). According to this strategy, the significant threshold for the meta-analysis was
set to 0.000694 (0.05/36SNPs/2models). Overall statistical power was calculated using
Quanto (v.12.4) assuming a log-additive model and a baseline risk of 3% for hematological
patients [36].
2.4. Linkage Disequilibrium (LD) and Haplotype Analysis
Haplotype frequencies were estimated using the expectation–maximization (EM)
algorithm and haplotypes were reconstructed using SNPtool and Haploview and block
structures were determined according to the method of Gabriel et al. [35]. Haplotype
association analysis was performed using the haplo.stats package and association estimates
were adjusted for age, sex, and country of origin.
2.5. Cell Isolation and Differentiation and Functional Analysis of the TNFSF4 and
MAPKAPK2 Variants
With the aim of determining whether those SNPs associated with IA risk had a role
in modulating immune responses, we performed in vitro stimulatory experiments and
we measured cytokine production (IFNγ, IL1Ra, IL1β, IL6, IL8, IL10, TNFα, IL17, and
IL22) after stimulation of peripheral blood mononuclear cells (PBMCs), whole blood, or
monocyte-derived macrophages (MDM) from 408 healthy subjects of the 500FG from the
Human Functional Genomics Project (HFGP) with Aspergillus fumigatus conidia. Given
the impact of steroid hormones in modulating immune responses, we also evaluated the
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correlation of SNPs with serum levels of 7 steroid hormones (androstenedione, cortisol,
11-deoxy-cortisol, 17-hydroxy progesterone, progesterone, testosterone, and 25 hydroxy
vitamin D3) in a subset of the HFGP subjects without hormonal replacement therapy or
oral contraceptives (n = 280). After log transformation, correlation between SNPs and
cytokine expression quantitative trait loci (cQTLs) or serum steroid hormone levels was
evaluated using linear regression adjusted for age and sex in R (http://www.r-project.org/).
Significance thresholds were set to 0.00185 and 0.0024 (0.05/3SNPs/9cytokines-7hormones)
for cQTL and steroid hormone analysis, respectively.
2.6. Correlation between TNFSF4 and MAPKAPK2 Polymorphisms and Cell Counts of
91 Blood-Derived Immune Cell Populations and Serum/Plasmatic Proteomic Profile
We also investigated whether TNFSF4 and MAPKAPK2 polymorphisms had an impact
on blood cell counts by analyzing a set of 91 manually annotated immune cell populations
and genotype data from the HFGP cohort that included 408 healthy subjects (Supplemen-
tary Table S2). Cell populations were measured by 10-color flow cytometry (Navios flow
cytometer, Beckman Coulter, Miami, Florida, USA) after blood sampling (2–3 h) and cell
count analysis was performed using the Kaluza software (Beckman Coulter, v.1.3). In order
to reduce inter-experimental noise and increase statistical power cell count, analysis was
performed by calculating parental and grandparental percentages, which were defined as
the percentage of a certain cell type within the subpopulation of cells from which it was
isolated [37]. Detailed laboratory protocols for cell isolation, reagents, gating, and flow
cytometry analysis have been reported elsewhere [38] and the accession number for the
raw flow cytometry data and analyzed data files are available upon request to the authors
(http://hfgp.bbmri.nl). A proteomic analysis was also performed in serum and plasma
samples from the HFGP cohort. Circulating proteins were measured using the commercial
Olink® Inflammation panel (Olink, Uppsala, Sweden) that resulted in the measurement of
103 different biomarkers (Supplementary Table S3). Protein levels were expressed on a log2-
scale as normalized protein expression values, and normalized using bridging samples
to correct for batch variation. Correlation between SNPs and protein levels or blood cell
counts was evaluated using linear regression adjusted for age and sex in R. Considering
the number of proteins (n = 103), cell populations (n = 91), and polymorphisms (n = 3)
tested, p-values of 0.00016 and 0.000183 were set as significant thresholds for the proteomic
and cell-level variation analysis.
2.7. Assessment of Fungicidal Activity
Finally, we also analyzed the impact of selected SNPs on fungicidal activity in human
monocyte-derived macrophages (MDM) from an independent cohort including 108 healthy
subjects. For that purpose, human MDM were infected with live A. fumigatus conidia at an
effector-to-target ratio of 1:10 for 1 h. After removing the non-ingested conidia, MDM were
allowed to kill internalized conidia for 2 h. To measure their fungicidal ability, MDM were
lysed by quickly freezing at −80 ◦C and thawing at 37 ◦C (releasing ingested conidia) and
cell lysates were mixed thoroughly, and serial dilutions were made in phosphate buffered
solution (PBS) and plated on Sabouraud dextrose agar. Following a 2-day incubation,
the number of colony-forming units (CFU) was enumerated and the percentage of CFU
inhibition was calculated. CFU counts of conidia treated in the same experimental con-
ditions but in the absence of macrophages were used as controls. Detailed information
about fungicidal experiments has been previously reported in detail [22,24,33]. Statistical
significance of in vitro fungicidal experiments was evaluated using an unpaired t-test
with or without Welch’s correction or Mann–Whitney U test. A p ≤ 0.05 was considered
significant (Prism v6.0).
2.8. In Silico Functional Analysis
Besides the functional analysis of the TNFSF4 and MAPKAPK2 polymorphisms re-
ported above, we also used the HaploReg SNP annotation tool to further investigate
the functional consequences of each specific variant (http://www.broadinstitute.org/
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mammals/haploreg/haploreg.php). Finally, we assessed whether any of the potentially
interesting markers correlated with mRNA expression levels of their respective genes using
data from the GTex portal (www.gtexportal.org/home/).
3. Results
3.1. Characteristics of Study Subjects
Overall, this two-stage case control study included 911 hematological patients at
high risk of IA. Of those, a total of 164 patients were diagnosed with proven or probable
IA. Demographic and clinical characteristics of the hematological patients included are
summarized in Table 1. Briefly, IA and non-IA groups had a similar age and underlying
disease distribution in both the discovery and replication cohorts. In addition, both IA and
non-IA groups showed a similar proportion of patients who underwent allogeneic stem
cell transplantation in both study cohorts, as shown in Table 1. Nonetheless, IA was more
frequently found in men than in women (p = 0.001) and, as expected, the use of antifungal
prophylaxis was less frequent among those patients diagnosed with IA (53.85% vs. 66.79%,
p = 0.008; Table 1).
3.2. Association Analysis and Functional Impact of TNFSF4 and MAPKAPK2 Polymorphisms
All SNPs analyzed were in HWE (p < 0.001) in the control group (non-IA cases). In
the discovery population, logistic regression analyses adjusted for age, sex, and coun-
try of origin revealed that each copy of the TNFSF4rs4357565C, TNFSF4rs7526628T, MAP-
KAPK2rs12126682G, MAPKAPK2rs11119267C, MAPKAPK2rs12123706T, and MAPKAPK2rs12137965G
alleles increased the risk of developing IA by 0.5 to 2-fold (OR = 1.47–2.06), whereas each
copy of the MAPKAPK2rs17013271T and MAPKAPK2rs4845123A alleles decreased the risk of
infection (OR = 0.48 and 0.59; Table 2).
Interestingly, we observed that most of these SNPs also impacted on IA risk according
to other models of inheritance (dominant or recessive), which reinforced the idea of a true
effect of the TNFSF4 and MAPKAPK2 loci in modulating disease risk. Considering these
potentially interesting findings, we decided to advance for replication those TNFSF4 and
MAPKAPK2 SNPs that showed significant results in the discovery population. Importantly,
the meta-analysis of the discovery and replication cohorts confirmed a consistent asso-
ciation of the TNFSF4rs7526628T/T genotype with an increased risk of developing IA that
remained statistically significant after correction for multiple testing (ORMeta-recessive = 2.25,
95% CI 1.46–3.46, p = 0.00022; Table 3). Even though it did not survive multiple testing
correction, we also found that carriers of the TNFSF4rs7526628T allele had an increased risk
of developing the infection, which indicated that a single copy of the risk allele might be
sufficient to drive disease susceptibility (ORMeta-dominant = 1.52, 95% CI 1.17–1.96, p = 0.0015;
Table 3).
In support of the hypothesis suggesting a role of the TNFSF4 in modulating IA risk, the
proteomic serum analysis of the 500FG cohort from the HFGP showed that carriers of the
TNFSF4rs7526628T allele had decreased serum concentration of TNFSF14 protein (p = 0.0027;
Figure 1A), a membrane-bound protein transiently expressed on activated T cells, natural
killer (NK) cells, and immature dendritic cells that is involved in promoting proinflam-
matory responses in multiple contexts and induces T cell proliferation and lung tissue
remodeling. In line with these findings, we also found in an independent cohort of healthy
donors that macrophages from carriers of the TNFSF4rs7526628T allele showed a decreased
fungicidal activity against A. fumigatus conidia when compared with those harboring the
most common TNFSF4rs7526628C/C genotype (PDominant = 0.048; Figure 1B). Although we
did not find any positive correlation between this SNP and cytokine production (IFNγ,
IL1Ra, IL1β, IL6, IL8, IL10, TNFα, IL17, and IL22) after stimulation of peripheral blood
mononuclear cells (PBMCs) with A. fumigatus conidia, these results together with our
genetic findings pointed to a weak but still functional effect of the TNFSF4rs7526628 SNP
that might influence the killing activity of macrophages and TNFSF14-mediated T cell
proliferation and lung tissue remodeling.
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Table 1. Baseline and clinical characteristic of patients with or without invasive aspergillosis (IA).
Discovery Population
Overall (n = 423) IA patients (n = 67) non-IA patients (n = 356) p value
Demographic variables
Age (Average ± SD) 52.35 ± 15.37 53.00 ± 12.69 52.23 ± 15.82 0.663
Sex ratio (male/female) 1.11 (222/200) 1.79 (43/24) 1.02 (179/176) 0.037
Hematological disease
AML 328 (77.54) 49 (73.13) 279 (78.37) 0.346
ALL 58 (13.71) 14 (20.90) 44 (12.36) 0.062
other 37 (08.75) 4 (05.97) 33 (09.27) 0.380
allo-SCT 137 (32.39) 20 (29.85) 117 (32.87) 0.629
Ever received prophylaxis † 244 (64.89) 22 (43.13) 222 (68.31) 0.0004
Replication population
Overall (n = 488) IA patients (n = 97) non-IA patients (n = 391) p value
Demographic variables
Age (Average ± SD) 50.90 ± 17.12 51.42 ± 15.72 50.76 ± 17.44 0.734
Sex ratio (male/female) 1.32 (278/210) 2.13 (66/31) 1.18 (212/179) 0.014
Hematological disease
AML 317 (64.96) 63 (65.95) 254 (64.96) 0.998
ALL 55 (11.27) 10 (10.31) 45 (11.51) 0.738
other 116 (23.77) 24 (24.74) 92 (23.53) 0.802
allo-SCT 251 (51.43) 54 (55.67) 197 (50.38) 0.351
Ever received prophylaxis † 193 (64.12) 41 (62.12) 152 (64.68) 0.702
Overall population
Overall (n = 911) IA patients (n = 164) non-IA patients (n = 747) p value
Demographic variables
Age (Average ± SD) 51.57 ± 16.35 52.07 ± 14.58 51.46 ± 16.71 0.637
Sex ratio (male/female) 1.22 (500/410) 1.98 (109/55) 1.10 (391/355) 0.001
Hematological disease
AML 645 (70.80) 112 (68.29) 533 (71.35) 0.435
ALL 113 (12.40) 24 (14.63) 89 (11.91) 0.339
other 153 (16.80) 28 (17.07) 125 (16.74) 0.916
allo-SCT 388 (42.59) 74 (45.12) 314 (42.03) 0.469
Ever received prophylaxis † 437 (64.55) 63 (53.85) 374 (66.79) 0.008
Abbreviations: allo-SCT: Allogeneic stem cell transplantation, AML: acute myeloid leukemia, ALL: acute lymphoid leukemia. p ≤ 0.05 was
considered significant and shown in bold. † Prophylaxis status was available in 677 patients, 376 subjects from the discovery cohort (51 IA
and 325 non-IA patients) and 301 subjects from the replication cohort (66 IA and 235 non-IA patients). Percentage was calculated according
to the number of subjects having prophylaxis information.




Figure 1. Correlation between the TNFSF4rs7526628 SNP and serum levels of TNFSF14 (pg/mL) (A) 
and fungicidal activity (%) of monocyte-derived macrophages (B). Grey line represents the mean 
with error bars (standard deviation). 
Table 2. Association analysis of selected SNPs within the TNFSF4 and MAPKAPK2 loci and IA 
risk in the discovery cohort. 
SNP_rsID Gene Risk Allele OR (95% CI) δ p OR (95% CI) Ϯ p OR (95% CI) ¥ p 
rs10489269 TNFSF4 A 1.23 (0.56–2.70) 0.61 1.08 (0.47–2.51) 0.86 NA (NA-NA) NA 
rs7518045 TNFSF4 G 1.08 (0.54–2.15) 0.83 0.91 (0.41–1.98) 0.80 NA (NA-NA) NA 
rs10489266 TNFSF4 G 0.56 (0.27–1.17) 0.10 0.58 (0.27–1.26) 0.15 NA (NA-NA) NA 
rs2205959 TNFSF4 G 0.85 (0.57–1.27) 0.44 1.11 (0.61–2.00) 0.73 0.46 (0.20–1.09) 0.058 
rs61828280 TNFSF4 G 0.63 (0.30–1.32) 0.20 0.66 (0.30–1.42) 0.27 NA (NA-NA) NA 
rs4916320 TNFSF4 G 0.76 (0.40–1.44) 0.38 0.77 (0.40–1.49) 0.43 NA (NA-NA) NA 
rs4357565 TNFSF4 C 1.73 (1.13–2.63) 0.011 2.13 (1.21–3.74) 0.0077 1.69 (0.67–4.24) 0.28 
rs1342038 TNFSF4 A 0.68 (0.44–1.03) 0.065 0.73 (0.41–1.30) 0.29 0.40 (0.16–1.02) 0.056 
rs947505 TNFSF4 A 1.17 (0.68–2.01) 0.58 1.07 (0.60–1.92) 0.82 4.17 (0.62–28.3) 0.17 
rs56307807 TNFSF4 C 0.95 (0.45–2.02) 0.90 0.85 (0.38–1.94) 0.70 4.32 (0.26–72.4) 0.33 
rs6425219 TNFSF4 T 1.08 (0.72–1.63) 0.71 1.07 (0.62–1.87) 0.80 1.19 (0.51–2.76) 0.69 
rs1418191 TNFSF4 C 1.47 (0.85–2.54) 0.18 1.63 (0.88–3.00) 0.13 0.87 (0.09–8.34) 0.90 
rs1578624 TNFSF4 C 0.86 (0.58–1.27) 0.44 0.73 (0.41–1.29) 0.29 0.97 (0.49–1.92) 0.92 
rs7526628 TNFSF4 T 1.72 (1.16–2.55) 0.0072 1.87 (1.02–3.42) 0.038 2.27 (1.22–4.20) 0.0068 
rs7549074 TNFSF4 C 1.43 (0.90–2.26) 0.14 1.34 (0.77–2.31) 0.30 2.95 (0.90–9.66) 0.089 
rs6700269 TNFSF4 T 1.74 (0.97–3.12) 0.075 1.94 (0.9–3.77) 0.059 1.56 (0.17–14.2) 0.71 
rs12140760 TNFSF4 A 0.83 (0.56–1.21) 0.33 0.79 (0.45–1.37) 0.40 0.75 (0.35–1.58) 0.44 
rs17013271 DYRK3 T 0.48 (0.32–0.73) 0.0004 0.48 (0.28–0.83) 0.0087 0.18 (0.05–0.59) 0.0005 
rs6540512 DYRK3 A 1.29 (078–2.11) 0.32 1.47 (0.83–2.58) 0.19 0.52 (0.06–4.37) 0.51 
rs12126682 DYRK3 G 1.47 (1.01–2.14) 0.044 1.62 (0.89–2.97) 0.11 1.77 (0.94–3.34) 0.084 
rs4845123 DYRK3 A 0.59 (0.38–0.90) 0.012 0.60 (0.35–1.03) 0.063 0.27 (0.08–0.89) 0.012 
rs17435120 DYRK3|MAPKAPK2 G 1.42 (0.98–2.06) 0.065 1.44 (0.80–2.58) 0.21 1.85 (0.98–3.49) 0.065 
rs12407425 DYRK3|MAPKAPK2 A 0.85 (0.46–1.58) 0.61 0.81 (0.41–1.59) 0.53 1.29 (0.14–11.8) 0.82 
rs11119267 DYRK3|MAPKAPK2 C 1.49 (1.00–2.22) 0.047 2.40 (1.26–4.59) 0.0051 1.07 (0.51–2.25) 0.86 
rs12038489 DYRK3|MAPKAPK2 A 1.03 (0.58–1.81) 0.92 1.08 (0.57–2.04) 0.82 0.67 (0.07–6.02) 0.71 
rs61815610 MAPKAPK2 T 0.79 (0.41–1.52) 0.47 0.82 (0.42–1.62) 0.56 NA (NA-NA) NA 
rs10863788 MAPKAPK2 A 0.73 (0.49–1.09) 0.12 0.83 (0.48–1.44) 0.51 0.37 (0.14–0.98) 0.027 
rs12123706 MAPKAPK2 T 1.74 (1.12–2.70) 0.014 2.35 (1.35–4.10) 0.0022 0.86 (0.24–3.12) 0.81 
rs4072677 MAPKAPK2 G 0.85 (0.58–1.24) 0.39 0.92 (0.52–1.63) 0.77 0.65 (0.31–1.35) 0.23 
rs61815626 MAPKAPK2 A 0.35 (0.10–1.17) 0.049 0.34 (0.10–1.18) 0.054 NA (NA-NA) NA 
rs12030124 MAPKAPK2 T 1.21 (0.72–2.03) 0.48 1.29 (0.72–2.28) 0.40 0. (0.09–6.73) 0.81 
rs4256810 MAPKAPK2 C 0.72 (0.46–1.13) 0.14 0.75 (0.44–1.29) 0.29 0.36 (0.08–1.56) 0.76 
rs28394820 MAPKAPK2 C 0.80 (0.47–1.35) 0.39 0.88 (0.50–1.55) 0.65 NA (NA-NA) NA 
rs4073250 MAPKAPK2 T 0.69 (0.43–1.11) 0.12 0.70 (0.39–1.25) 0.22 0.35 (0.08–1.55) 0.11 
rs7515374 MAPKAPK2||IL10 C 0.86 (0.58–1.28) 0.46 0.88 (0.50–1.54) 0.66 0.71 (0.58–1.28) 0.46 
rs12137965 MAPKAPK2||IL10 G 2.06 (1.34–3.16) 0.0011  3.01 (1.68–5.38) 0.0001 1.38 (0.48–3.95) 0.56 
Figure 1. Correlation between the TNFSF4rs7526628 SNP and serum levels of TNFSF14 (pg/mL) (A) and fungicidal activity
(%) of monocyte-derived macrophages (B). Grey line represents th mean with error bars (standard d viation).
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Table 2. Association analysis of selected SNPs within the TNFSF4 and MAPKAPK2 loci and IA risk in the discovery cohort.
SNP_rsID Gene Risk Allele OR (95% CI) δ p OR (95% CI)
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All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance. 
Table 3. Association analysis of the most significant SNPs within TNFSF4 and MAPKAPK2 regions 
in the meta-analysis of study cohorts. 
  
Discovery Population 
(n = 423) 
Replication Population 
(n = 488) 
Meta-Analysis 





OR (95% CI) δ p OR (95% CI) δ p OR (95% CI) δ p PHet 
rs4357565 C 1.73 (1.13–2.63) 0.011 0.95 (0.64–1.42) 0.81 1.26 (0.94–1.68) 0.118 0.043 
rs4357565 C 1.69 (0.67–4.24) ¥ 0.28 1.31 (0.55–3.11) ¥ 0.55 1.48 (0.79–2.78) ¥ 0.227 0.693 
rs7526628 T 1.72 (1.16–2.55) 0.0072 1.38 (0.98–1.94) 0.068 1.52 (1.17–1.96) 0.0015 0.41 
rs7526628 T 2.27 (1.22–4.20) ¥ 0.0068 2.23 (1.22–4.06) ¥ 0.011 2.25 (1.46–3.46) ¥ 
0.0002
2 0.97 
rs17013271 T 0.48 (0.32–0.73) 0.0004 0.85 (0.58–1.23) 0.38 0.66 (0.50–0.87) 0.0029 0.05 
rs17013271 T 0.48 (0.28–0.83)  0.0087 0.73 (0.44–1.23)  0.24 0.60 (0.41–0.87)  0.0071 0.27 
rs12126682 G 1.47 (1.01–2.14) 0.044 0.82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
rs12126682 G 1.62 (0.89–2.97)  0.11 0.81 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritance was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant after correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
p OR (95% CI) ¥ p
rs10489269 TNFSF4 A 1.23 (0.56–2.70) 0.61 1.08 (0.47–2.51) 0.86 NA (NA-NA) NA
rs7518045 TNFSF4 G 1.08 (0.54–2.15) 0.83 0.91 (0.41–1.98) 0.80 NA (NA-NA) NA
rs10489266 TNFSF4 G 0.56 (0.27–1.17) 0.10 0.58 (0.27–1.26) 0.15 NA (NA-NA) NA
rs2205959 TNFSF4 G 0.85 (0.57–1.27) 0.44 1.11 (0.61–2.00) 0.73 0.46 (0.20–1.09) 0.058
rs61828280 TNFSF4 G 0.63 (0.30–1.32) 0.20 0.66 (0.30–1.42) 0.27 NA (NA-NA) NA
rs4916320 TNFSF4 G 0.76 (0.40–1.44) 0.38 0.77 (0.40–1.49) 0.43 NA (NA-NA) NA
rs4357565 TNFSF4 C 1.73 (1.13–2.63) 0.011 2.13 (1.21–3.74) 0.0077 1.69 (0.67–4.24) 0.28
rs1342038 TNFSF4 A 0.68 (0.44–1.03) 0.065 0.73 (0.41–1.30) 0.29 0.40 (0.16–1.02) 0.056
rs947505 TNFSF4 A 1.17 (0.68– .01) 0.58 1.07 (0.60–1.92) 0.8 4.17 (0.62–28.3) 0.17
rs56307807 TNFSF4 C 0.95 (0.45– .02) 0.90 0.85 (0.38–1.94) 0.70 4.32 (0.26–72.4) 0.33
rs6425219 TNFSF4 T 1.08 (0.72–1.63) 0.71 1.07 (0.62–1.87) 80 1.19 (0.51–2.76) 0.69
rs1418191 TNFSF4 C 1.47 (0.85–2.54) 0.18 1.63 (0.88–3.00) 0.13 0.87 (0.09–8.34) 0.90
rs1578624 TNFSF4 C 0.86 (0.58–1. 7) 0.44 0.73 (0.41–1.29) 0 29 97 (0.49–1.92) 0.92
rs7526628 TNFSF4 T 1.72 (1.16–2.55) 0.0072 1.87 (1.02–3.42) 0.038 2.27 (1.22–4.20) 0.0068
rs7549074 TNFSF4 C 1.43 (0.90–2.26) 0.14 1.34 (0.77–2.3 ) 0.3 2.9 (0.9 –9.66) 0.089
rs6700269 TNFSF4 T 1.74 (0.97–3.12) 0.075 1.94 (0.9–3.77) 0.059 1.56 (0.17–14.2) 0.71
rs12140760 TNFSF4 A 0.83 (0.56–1.21) 0.33 0.79 (0.45–1.37) 0.40 0.75 (0.35–1.58) 0.44
rs17013271 DYRK3 T 0.48 (0.32–0.73) 0.0004 0.48 (0.28–0.83) 0.0087 0.18 (0.05–0.59) 0.0005
rs6540512 DYRK3 A 1.29 (078–2.11) 0.32 1.47 (0.83–2.58) 0.19 0.52 (0.06–4.37) 0.51
rs12126682 DYRK3 G 1.47 (1.01–2.14) 0.044 1.62 (0.89–2.97) 0.11 1.77 (0.94–3.34) 0.084
rs4845123 DYRK3 A 0.59 (0.38–0.90) 0.012 0.60 (0.35–1.03) 0.063 0.27 (0.08–0.89) 0.012
rs17435120 DYRK3|MAPKAPK2 G 1.42 (0.98–2.06) 0.065 1.44 (0.80–2.58) 0.21 1.85 (0.98–3.49) 0.065
rs12407425 DYRK3|MAPKAPK2 A 0.8 (0.46–1.58) 0.61 0.81 (0.41–1.59) 0.53 1.29 (0.14–11.8) 0.82
rs11119267 DYRK3|MAPKAPK2 C 1.49 (1.00–2.22) 0.047 2.40 (1.26–4.59) 0.0051 1.07 (0.51–2.25) 0.86
rs12038489 DYRK3|MAPKAPK2 A 1.03 (0.58–1.81) 0.92 1.08 (0.57–2.04) 0.82 0.67 (0.07–6.02) 0.71
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All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance. 
Table 3. Association analysis of the most significant SNPs within TNFSF4 and MAPKAPK2 regions 
in the meta-analysis of study cohorts. 
  
Discovery Population 
(n = 423) 
Replication Population 
(n = 488) 
Meta-Analysis 





OR (95% CI) δ p OR (95% CI) δ p OR (95% CI) δ p PHet 
rs4357565 C 1.73 (1.13–2.63) 0.011 0.95 (0.64–1.42) 0.81 1.26 (0.94–1.68) 0.118 0.043 
rs4357565 C 1.69 (0.67–4.24) ¥ 0.28 1.31 (0.55–3.11) ¥ 0.55 1.48 (0.79–2.78) ¥ 0.227 0.693 
rs7526628 T 1.72 (1.16–2.55) 0.0072 1.38 (0.98–1.94) 0.068 1.52 (1.17–1.96) 0.0015 0.41 
rs7526628 T 2.27 (1.22–4.20) ¥ 0.0068 2.23 (1.22–4.06) ¥ 0.011 2.25 (1.46–3.46) ¥ 
0.0002
2 0.97 
rs17013271 T 0.48 (0.32–0.73) 0.0004 0.85 (0.58–1.23) 0.38 0.66 (0.50–0.87) 0.0029 0.05 
rs17013271 T 0.48 (0.28–0.83)  0.0087 0.73 (0.44–1.23)  0.24 0.60 (0.41–0.87)  0.0071 0.27 
rs12126682 G 1.47 (1.01–2.14) 0.044 0.82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
rs12126682 G 1.62 (0.89–2.97)  0.11 0.81 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritance was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant after correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
p OR (95% CI) ¥ p
rs61815610 MAPKAPK2 T 0.79 (0.41–1.52) 0.47 0.82 (0.42–1.62) 0.56 NA (NA-NA) NA
rs10863788 MAPKAPK2 A 0.73 (0.49–1.09) 0.12 0.83 (0.48–1.44) 0.51 0.37 (0.14–0.98) 0.027
rs12123706 MAPKAPK2 T 1.74 (1.12–2.70) 0.014 2.35 (1.35–4.10) 0.0022 0.86 (0.24–3.12) 0.81
rs4072677 MAPKAPK2 G 0.85 (0.58–1.24) 0.39 0.92 (0.52–1.63) 0.77 0.65 (0.31–1.35) 0.23
rs61815626 MAPKAPK2 A 0.35 (0.10–1.17) 0.049 0.34 (0.10–1.18) 0.054 NA (NA-NA) NA
rs12030124 MAPKAPK2 T 1.21 (0.72–2.03) 0.48 1.29 (0.72–2.28) 0.40 0. (0.09–6.73) 0.81
rs4256810 MAPKAPK2 C 0.72 (0.46–1.13) 0.14 0.75 (0.44–1.29) 0.29 0.36 (0.08–1.56) 0.76
rs28394820 MAPKAPK2 C 0.80 (0.47–1.35) 0.39 0.88 (0.50–1.55) 0.65 NA (NA-NA) NA
rs4073250 MAPKAPK2 T 0.69 (0.43–1.11) 0.12 0.70 (0.39–1.25) 0.2 .35 (0.08–1.55) 0.11
rs7515374 MAPKAPK2||IL10 C 0.86 (0. 8–1.28) 0.46 0.88 (0.50–1.54) 0.66 0.71 (0.58–1.28) 0.46
rs12137965 MAPKAPK2||IL10 G 2.06 ( .34–3. 6) 0.0011 3.01 (1.68– .38) 0.0001 1.38 (0.48–3.95) 0.56
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression analysis assuming a log-additive model of inheritance.
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Discovery Population 
(n = 423) 
Replication Population 
(n = 488) 
Meta-Analysis 





OR (95% CI) δ p OR (95% CI) δ p OR (95% CI) δ p PHet 
rs4357565 C 1.73 (1.13–2.63) 0.011 0.95 (0.64–1.42) 0.81 1.26 (0.94–1.68) 0.118 0.043 
rs4357565 C 1.69 (0.67–4.24) ¥ 0.28 1.31 (0.55–3.11) ¥ 0.55 1.48 (0.79–2.78) ¥ 0.227 0.693 
rs7526628 T 1.72 (1.16–2.55) 0.0072 1.38 (0.98–1.94) 0.068 1.52 (1.17–1.96) 0.0015 0.41 
rs7526628 T 2.27 (1.22–4.20) ¥ 0.0068 2.23 (1.22–4.06) ¥ 0.011 2.25 (1.46–3.46) ¥ 
0.0002
2 0.97 
rs17013271 T 0.48 (0.32–0.73) 0.0004 0.85 (0.58–1. 3) 0.38 0.66 (0.50–0.87) 0.0029 0.05 
rs17013271 T 0.48 (0.28–0.83)  0.0 87 0.73 (0.44–1.23)  0.24 0.60 (0.41–0.87)  0.0071 0.27 
rs12126682 G 1.47 (1.01–2.14) 0.044 0.82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
r 12126682 G 1.62 (0.89–2.97)  0.11 0.81 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritance was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant after correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
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Table 3. Association analysis of the most significant SNPs within TNFSF4 and MAPKAPK2 regions in the meta-analysis of study cohorts.
Discovery Population (n = 423) Replication Population (n = 488) Meta-Analysis (n = 911)
SNP_rsID Risk Allele OR (95% CI) δ p OR (95% CI) δ p OR (95% CI) δ p PHet
rs4357565 C 1.73 (1.13–2.63) 0.011 0.95 (0.64–1.42) 0.81 1.26 (0.94–1.68) 0.118 0.043
rs4357565 C 1.69 (0.67–4.24) ¥ 0.28 1.31 (0.55–3.11) ¥ 0.55 1.48 (0.79–2.78) ¥ 0.227 0.693
rs7526628 T 1.72 (1.16–2.55) 0.0072 1.38 (0.98–1.94) 0.068 1.52 (1.17–1.96) 0.0015 0.41
rs7526628 T 2.27 (1.22–4.20) ¥ 0.0068 2.23 (1.22–4.06) ¥ 0.011 2.25 (1.46–3.46) ¥ 0.00022 0.97
rs17013271 T 0.48 (0.32–0.73) 0.0004 0.85 (0.58–1.23) 0.38 0.66 (0.50–0.87) 0.0029 0.05
rs17013271 T 0.48 (0.28–0.83)
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rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
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All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritance was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant after correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
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rs12 23706 T 2.35 (1.35– .10)  .0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
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All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of heritance. Ϯ Logistic regression analysis assuming a 
d mi nt model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the oth r hand, the meta-analysis f the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an incre sed risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
m te  to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect f the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritance was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant fter correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G gen type also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
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domina t model of inheritan . ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the othe  hand, the meta-analysi of the iscovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In lin  with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) wh reas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inherita ce was assumed (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these gen tic associations r mained significant after correction for multiple testing, we found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.0071 0.27
rs12126682 G 1.47 (1.01–2.14) 0.044 0.82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032
rs12126682 G 1.62 (0.89–2.97)
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analysis assuming a log-additiv  mode  of inherit c . Ϯ Logistic gressi  analysis assuming a 
dominant model of inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the disco ery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carri s of the 
MAPKAPK2rs11119267C allele ha  an increased risk of d vel ping the inf ction (ORMeta-domi ant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPK PK2rs1701327 T allele was esti-
mated to de rease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; able 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inheritan e was assumed (C/C vs. C/T+T/T), w ich rei forced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none f 
these genetic associations remained significant after correction f r multiple testin , w  found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased lev ls of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that ca riers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
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rs12126682 G 1.47 (1.01–2.14) 0.044 .82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
rs12 26682 G 1.62 (0.89–2.97)  0.11 0. 1 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119 67 C 1.49 (1.00–2.22) .047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0 51 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1. 2–2.70) 0.014 .84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12 23706 T 2.35 (1.35– .10)  .0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyse  were adjusted for ag , sex, and country of orig n. p < 0.05 in bold. δ i ti  r r s i  
analysis assuming a log-addi iv  m de  of heritance. Ϯ Logistic gressi  analysis ssuming a 
d mi nt model inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the oth r hand, the met -analysi    discovery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of d veloping IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2. 5, p = 0.0017). In line with this finding, we found that carri rs of t e 
APKAPK2rs11119267C allele ha  an incre sed risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs170132 1T allele was esti-
m te  to de rease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect f the MAPKAPK2rs17013271 SNP  IA risk was also ob erved when a dominant model 
of inhe itan e was assum d (C/C vs. C/T+T/T), which reinforced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant fter correction for multiple test ng, w  fou d tha  
carrier   e risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G gen type also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.41 1.08 (0.73–1.60) 0.685 0.086
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822
rs11119267 C 2.40 (1.26–4.59)
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2 0.97 
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rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of orig n. p < 0.05 in b ld. δ Logistic regressio  
analysis assuming a log-additiv  mode  of inherit c . Ϯ Logistic ressi  analysis assuming a 
dominant model of inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the disco ery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carri s f the 
MAPKAPK2rs11119267C allele ha  an increased risk f d vel ping the inf cti n (ORMeta-domi ant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPK PK2rs1701327 T allele was esti-
mated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; able 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inherita e was assumed (C/C vs. C/T+T/T), w ich rei f rced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none f 
these genetic associations remained significant after correction f r multiple testin , w  found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased lev ls of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that ca riers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.0051 1.55 (0.86–2.78)
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rs11119 67 C 1.49 (1.00–2.22) .047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0 51 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1. 2–2.70) 0.014 .84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12 23706 T 2.35 (1.35– .10)  .0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyse  were adjusted for ag , sex, and country of orig n. p < 0.05 in b ld. δ Logistic regression 
analysis assuming a log-addi iv  m de  of heritance. Ϯ Logistic ressi  analysis assuming a 
d mi nt model inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the oth r hand, the met -analysi    discovery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas  the risk of developing IA by 60% ( -
Meta-additive = 1.60, 95% CI 1.19–2. 5, p = 0.0017). In line with this finding, we found that carriers of the 
APKAPK2rs11119267C allele ha  an incre sed risk of developing the infecti n (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
m te  to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect f the MAPKAPK2rs17013271 SNP  IA risk was also observed when a dominant model 
of inhe ita e was assum d (C/C vs. C/T+T/T), which rei f rce  the role of he MAPK PK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant fter correction for multiple testing, w  found that 
carrier   e risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G gen type also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.13 1.89 (1.22–2.92) 0.0040 0.326
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020
rs12123706 T 2.35 (1.35–4.10)
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rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
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All analyses were adjusted for age, sex, and country of orig n. p < 0.05 in b ld. δ Logistic regressio  
analysis assuming a log-additiv  mode  of inherit c . Ϯ Logistic ressi  analysis assuming a 
dominant model of inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the disco ery and replication study coho ts showed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carri s of the 
MAPKAPK2rs11119267C allele ha  an increased risk f d vel ping the inf cti n (ORMeta-domi ant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPK PK2rs1701327 T allele was esti-
ated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; able 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inherita e was assumed (C/C vs. C/T+T/T), w ich rei f rced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none f 
these genetic associations remained significant after correction f r multiple testin , w  found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased lev ls of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that ca riers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.0022 0.88 (0.52–1.48)
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All analyse  were adjusted for ag , sex, and country of orig n. p < 0.05 in b ld. δ Logistic regression 
analysis assuming a log-addi iv  m de  of heritance. Ϯ Logistic ressi  analysis assuming a 
d mi nt model inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the oth r hand, the met -analysi    discovery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2. 5, p = 0.0017). In line with this finding, we found that carriers of the 
APKAPK2rs11119267C allele ha  an incre sed risk of developing the infecti n (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
te  to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect f the MAPKAPK2rs17013271 SNP  IA risk was also observed when a dominant model 
of inhe ita e was assum d (C/C vs. C/T+T/T), which reinf rced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant fter correction for multiple testing, w  found that 
carrier   e risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G gen type also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.63 1.40 (0.95–2.04) 0.086 0.012
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11
rs12137965 G 3.01 (1.68–5.38)
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rs17013271 T 0.48 (0.28–0.83)  0.0087 0.73 (0.44–1.23)  0.24 0.60 (0.41–0.87)  0.0071 0.27 
rs12126682 G 1.47 (1.01–2.14) 0.044 0.82 (0.56–1.19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
rs12126682 G 1.62 (0.89–2.97)  0.11 0.81 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0.97–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of orig n. p < 0.05 in b ld. δ Logistic regressio  
analysis assuming a log-additiv  mode  of inherit c . Ϯ Logistic ressi  analysis assuming a 
dominant model of inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the disco ery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carri s of the 
MAPKAPK2rs11119267C allele ha  an increased risk f d vel ping the inf cti n (ORMeta-domi ant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPK PK2rs1701327 T allele was esti-
ated to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; able 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inherita e was assumed (C/C vs. C/T+T/T), w ich rei f rced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none f 
these genetic associations remained significant after correction f r multiple testin , w  found that 
carriers of the risk MAPKAPK2rs12137965G allele showed increased lev ls of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that ca riers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.0001 1.26 (0.77–2.08)
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d mi nt model inheritance. ¥ Logistic regr ssion nalysis assuming a recessive model of inher-
itance.On the oth r hand, the met -analysi    discovery and replication study coho ts sh wed 
that each copy of the MAPKAPK2rs12137965G allele increas d the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2. 5, p = 0.0017). In line with this finding, we found that carriers of the 
APKAPK2rs11119267C allele ha  an incre sed risk of developing the infecti n (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) whereas each copy of the MAPKAPK2rs17013271T allele was esti-
te  to decrease the risk of developing IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect f the MAPKAPK2rs17013271 SNP  IA risk was also observed when a dominant model 
of inhe ita e was assum d (C/C vs. C/T+T/T), which reinf rced the role of he MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these genetic associations remained significant fter correction for multiple testing, w  found that 
carrier   e risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G gen type also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.36 1.81 (1.25–2.65)
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that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2. 5, p = 0.0017). In lin  with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
95% CI 1–22-2.92, p = 0.0040; Table 3) wh reas each copy of the MAPKAPK2rs17013271T allele was esti-
mated to decrease the risk f d veloping IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 
3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model 
of inherita ce was ass med (C/C vs. C/T+T/T), which reinforced the role of the MAPKAPK2 gene 
in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of 
these gen tic a sociations r mained significant after correction for multiple testing, we found that 
carri rs of the risk MAPKAPK2rs12137965G allele showed increased levels of CD38+IgM-IgD- plas-
mablasts in blood (p = 0.00086; Figure 2A). In addition, we observed that carriers of the MAP-
KAPK2rs12137965G/G genotype also showed decreased levels of thymic stromal lymphopoietin (TSLP) 
in serum (p = 0.00097; Figure 2B). 
0.0019 0.030
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression analysis assuming a log-additive model of inheritance.
J. Fungi 2021, 7, x FOR PEER REVIEW 9 of 17 
 
 
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
d minant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance. 
Table 3. Associatio analysis of the most significant SNPs within TNFSF4 and MAPKAPK2 regions 
in the meta-analysis of study c horts. 
  
Discovery Population 
(n = 423) 
Replication Population 
(n = 88) 
Meta-Analysis 





OR (95% CI) δ p OR (95% CI) δ p OR (95% CI) δ p PHet 
rs4357565 C 1.73 (1.13–2.63) 0. 11 0.95 (0.64–1.42) 0.81 1.26 (0.94–1.68) 0.118 0.043 
rs4357565 C 1.69 (0.67–4.24) ¥ 0.2  .31 (0.55–3.11) ¥ 0.55 1.48 (0.79–2.78) ¥ 0.227 0.693 
rs7526 28 T 1.72 (1.16–2.55) 0.0  1 38 (0.98–1.94) 0.068 1.52 (1.17–1.96) 0.0015 0.41 
rs75 6628 T 2.27 (1.22–4.20) ¥ 0.0 68 2.23 (1.22–4.06) ¥ 0.011 2 5 (1.46–3.46) ¥ 
0.0002
2 0.97 
rs17013271 T 0.48 (0.32–0.73) .0 04 0.85 (0.58–1.23) 0.38 0.66 (0.50–0.87) 0.0029 0.05 
rs17013271 T 0.48 (0.28–0.83)  .0 87 0 73 (0.44–1.23)  0.24 0.60 (0.41–0.87)  0.0071 0.27 
r 12126682 G 1.47 (1.01–2 14) 0.044 0.82 (0.56– .19) 0.29 1.10 (0.84–1.43) 0.486 0.032 
rs12126682 G 1.62 (0.89–2.97)  0.11 0.81 (0.48–1.34)  0.41 1.08 (0.73–1.60) 0.685 0.086 
rs11119267 C 1.49 (1.00–2.22) 0.047 1.40 (0. 7–2.02) 0.069 1.44 (1.10–1.89) 0.0080 0.822 
rs11119267 C 2.40 (1.26–4.59)  0.0051 1.55 (0.86–2.78)  0.13 1.89 (1.22–2.92) 0.0040 0.326 
rs12123706 T 1.74 (1.12–2.70) 0.014 0.84 (0.55–1.29) 0.43 1.20 (0.88–1.62) 0.254 0.020 
rs12123706 T 2.35 (1.35–4.10)  0.0022 0.88 (0.52–1.48)  0.63 1.40 (0.95–2.04) 0.086 0.012 
rs12137965 G 2.06 (1.34–3.16) 0.0011 1.28 (0.85–1.91) 0.24 1.60 (1.19–2.15) 0.0017 0.11 
rs12137965 G 3.01 (1.68–5.38)  0.0001 1.26 (0.77–2.08)  0.36 1.81 (1.25–2.65)  0.0019 0.030 
All analyses were adjusted for age, sex, and country of origin. p < 0.05 in bold. δ Logistic regression 
analysis assuming a log-additive model of inheritance. Ϯ Logistic regression analysis assuming a 
dominant model of inheritance. ¥ Logistic regression analysis assuming a recessive model of inher-
itance.On the other hand, the meta-analysis of the discovery and replication study cohorts showed 
that each copy of the MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (OR-
Meta-additive = 1.60, 95% CI 1.19–2.15, p = 0.0017). In line with this finding, we found that carriers of the 
MAPKAPK2rs11119267C allele had an increased risk of developing the infection (ORMeta-dominant = 1.89, 
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Logistic regression analysis assuming a dominant
model of inheritance. ¥ Logisti reg ession analysis assuming a recessive model of inherita ce.On the ther hand, the m ta- alysis of the discovery and replicat on tudy cohorts showed that each copy of the
MAPKAPK2rs12137965G allele increased the risk of developing IA by 60% (ORMeta-additive = 1 60, 95% CI 1.19–2.15, p = 0.00 7). In line with this finding, we found that carriers of the MAPKAPK2rs11119267C allele had
an increased risk of developing the infection (ORMeta-dominant = 1.89, 95% CI 1.22– .92, p = 0.0040; Table 3) whereas each copy of he MAPKAPK2rs17013271T allele was estimated to decrease the risk of developing
IA (ORMeta-additive = 0.66, 95% CI 0.50–0.87, p = 0.0029; Table 3). The effect of the MAPKAPK2rs17013271 SNP on IA risk was also observed when a dominant model of inheritance was assumed (C/C vs. C/T+T/T),
which reinforced the role of the MAPKAPK2 gene in modulating IA risk (ORMeta-dominant = 0.60, 95% CI 0.41–0.87, p = 0.0071; Table 3). Although none of these genetic associations remained significant after
correction for multiple testing, we found that carriers of the risk MAPKAPK2rs12137965G ll le sh wed increased evel f CD38+IgM-IgD- plasmablasts in blo d (p = 0.00086; Figure 2A). In addition, we observed
that carriers of the MAPKAPK2rs12137965G/G genotype also showed decreased vels of thymic stromal lymphopoietin (TSLP) in serum (p = 0.0009 ; Figure B).
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= 0.00018; Figure 3B) and classical monocytes (defined as CD14+CD16- cells; p = 0.00023; Figure 
3C) in blood. Although only the association of the MAPKAPK2rs17013271T allele with decreased num-
bers of CD14+ cells remained statistically significant after multiple testing correction (p ≤ 0.00018), 
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4. Discussion
This study reports for the first time the association of TNFSF4 and MAPKAPK2 poly-
morphisms with the risk of developing IA infection. The most significant association with
IA risk was found for the TNFSF4rs7526628 polymorphism in the second intron of the TN-
FSF4 locus. Thus, carriers of the TNFSF4rs7526628T/T genotype had a 2-fold increased risk of
IA when compared with those harboring the most common allele. TNFSF4 gene maps on
chromosome 1q25 and encodes for a costimulatory molecule expressed mostly in mature
DCs, B cells, and macrophages [39] that is essential to acquire antigen presenting cell
function [40]. Besides antigen presenting cells, TNFSF4 expression has also been found in
regulatory T (Treg) cells where it promotes cell development and regulates cell homeostasis,
and Treg suppressive activity thus controlling T-cell tolerance [41]. In addition, TNFSF4
has been implicated in the control of Th2 priming, effector cell function, cell survival,
and memory cell induction that drive lung inflammation [42,43]. Previous studies have
also suggested that TNFSF4 expression is upregulated during infection [44] and that the
presence of genetic polymorphisms within the TNFSF4 locus is associated with the risk
of developing immune-related diseases [45,46] and determining stem cell transplantation
outcomes [47]. Given that only the TNFSF4rs7526628 SNP showed a consistent effect on IA
risk in both the discovery and replication populations, we hypothesize that this SNP might
be the causative variant influencing innate immune responses against A. fumigatus. In
support of this notion, we found that macrophages from carriers of the TNFSF4rs7526628T
allele showed a decreased fungicidal activity when compared with those carrying the
most common genotype. In addition, we found that carriers of the TNFSF4rs7526628T/T
genotype showed decreased serum levels of TNFSF14, a protein that has been shown to
be involved in the development of pro-inflammatory responses but also in lung tissue
remodeling [48] and lung fibrosis [49]. A growing body of evidence suggests that TNFSF14
through interaction with its receptors, including herpes virus entry mediator (HVEM) and
lymphotoxin beta receptor (LTβR) can induce T cell proliferation, airway remodeling, and
proinflammatory responses in a broad range of contexts and, therefore, it is plausible to
think that decreased serum levels of this circulating protein might increase susceptibility to
IA. In line with the hypothesis suggesting a role of the TNFSF4 locus in determining the
response to A. fumigatus, Nguyen and coworkers demonstrated that vitamin D3 deficiency,
which increased the expression of TNFSF4 on lung CD11C+ cells, was essential for the
promotion of Th2 immune responses during A. fumigatus infection [50]. Similarly, Kreindler
and coworkers reported that vitamin D3 attenuated in a TNFSF4-dependent manner Th2
immune responses to A. fumigatus mounted by CD4+T cells from cystic fibrosis patients
with allergic bronchopulmonary aspergillosis [51]. Although at this point it was tempting
to speculate that the TNFSF4rs7526628 SNP might be biologically functional and drive sus-
ceptibility to IA by inhibiting TNFSF4- and TNFSF14-mediated proinflammatory responses
and fungal clearance mediated by macrophages and DCs, we recognize that none of the
functional findings attributed to the TNFSF4rs7526628 SNP remained statistically significant
after correction for multiple testing and that, therefore, additional functional studies are
still warranted to unravel the exact mechanisms by which this SNP is affecting immune
responses against A. fumigatus.
Another interesting result of this study was the consistent association of three tag-
ging variants within the MAPKAPK2|DYRK3 region with the risk of developing IA. The
MAPKAPK2 gene is located downstream of IL10 receptor and within the IL10 gene cluster
including the IL10 locus but also those genes encoding for relevant cytokines, such as IL19,
IL20, and IL24. The strongest effect on IA risk was found for the MAPKAPK2rs17013271 and
MAPKAPK2rs12137965 SNPs that are located upstream and downstream of the MAPKAPK2
gene, respectively. While carriers of the MAPKAPK2rs12137965G allele had an increased risk
of developing IA, those harboring the MAPKAPK2rs17013271T allele showed a decreased
risk of developing the infection. Mechanistically, we found that carriers of the risk MAP-
KAPK2rs12137965G allele showed an increased number of CD38+IgM-IgD- B cells, whereas
carriers of the MAPKAPK2rs12137965G/G genotype showed decreased serum levels of TSLP,
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a protein expressed by human airway epithelial cells [52] and smooth muscle cells [53]
but also DCs [54]. TSLP expression has been associated with the activation of NF-κB
downstream of toll-like receptors (TLRs) [52,55], NOD2 expression [56], and stimulation
of human airway smooth muscle cells with IL1β and TNFα [53], as well as pulmonary
infections [57,58]. Furthermore, TSLP has been implicated in multiple immune processes
including maturation of blood CD11C+ dendritic cells, induction of TNFSF4 protein expres-
sion on DCs to prime naive CD4+ T cells to differentiate into proinflammatory Th2 cells [59],
maintenance and expansion of Th2 central memory T cells [60], and differentiation of Treg
cells [61] but also B lymphopoiesis [62]. In addition, TSLP expression is dependent on
NK-κB and AP-1 [63] but also the p38MAPK/MAPKAPK2 signaling pathway [53] in
such a way that suppression of the p38MAPK drastically decreases TSLP secretion after
the stimulation with IL1β and TNFα [53]. Given that overexpression of TSLP inhibits B
lymphopoiesis [62], induces TNFSF4-mediated Th2 immune responses, and given that its
production is controlled by the p38MAPK/MAPKAPK2 pathway, it seems conceivable to
suggest that the presence of SNPs within the MAPKAPK2 locus that correlate with serum
TSLP and blood B cell levels might influence the risk of developing IA. In support of
this hypothesis, we also found that carriers of the MAPKAPK2rs17013271T allele, who had a
decreased risk of developing IA, showed lower blood numbers of CD27-IgM-IgD- B cells
(among other B cell subpopulations) when compared with those carrying the most common
genotype, but also significantly lower numbers of CD14+ and CD14+CD16- monocytes,
which reinforced the idea of a role of the MAPKAPK2 gene in modulating myeloid cell
proliferation. In line with our findings, an interesting study demonstrated that the activa-
tion of both p38MAPK and MAPKAPK2 was required for B cell proliferation and that the
inhibition of p38MAPK activity in vivo with a cell-permeable inhibitor (SB203580), under
conditions that prevented MAPKAPK2 activation, strongly perturbed CD40-induced B cell
proliferation and TNFα-induced NFκB activation [64]. Similarly, Sutherland and coworkers
(1996) reported that upon cross-linking of CD40, MAPKAPK2 was able to promote B cell
survival [65]. In addition, although the role of MAPKAPK2 in the modulating B cell prolif-
eration during infection is poorly studied, the use of SB203580 was shown to reduce Dengue
virus-induced liver inflammation and tissue injury by decreasing MAPKAPK2-dependent
cytokine (TNFα, IL6, and IL10) and chemokine (RANTES and IP-10) production [66]. In
addition, another study showed that miR-125a, which is involved in determining the com-
mitment and immunosuppressive capacity of Treg cells, was highly expressed in a model
of parasitic infection and that it mediated its action through the regulation of both TNFSF4
and MAPKAPK2 genes [67]. Considering our genetic and functional results but also those
reported in the literature, we suggest that the presence of functional polymorphisms within
the TNFSF4 and MAPKAPK2 genes influence the risk of developing IA in susceptible hosts
by modulating TNFSF14- and TSLP-mediated immune responses but also myeloid cell
proliferation. However, although we have provided some insights about the functional role
of the TNFSF4 and MAPKAPK2 polymorphisms in determining the risk of IA, we believe
that additional studies are still warranted to identify the exact mechanisms by which these
loci modulate the risk of fungal infection. In silico data from HaploReg showed that the
TNFSF4rs7526628, MAPKAPK2rs12137965, and MAPKAPK2rs17013271 SNPs were located among
histone marks in multiple immune cell types including primary T CD8+ naïve cells, T
helper, and T regulatory cells but also primary B cells. In addition, in silico analysis showed
that the MAPKAPK2rs12137965 and MAPKAPK2rs17013271 SNPs were involved in determining
chromatin states on these cells, which reinforced the idea of a functional effect of these
SNPs to modulate the risk of IA infection.
To conclude, it is necessary to mention that this study has both strengths and weak-
nesses. A strength is the large population size of the aspBIOmics population that allowed a
sufficiently powered association analysis to detect small effects. Based on the genotype
frequencies observed in the global cohort, we had 80% of power (log-additive model) to
detect an OR of 1.76 at alpha = 0.00068 (multiple testing threshold) for an SNP with a
minor allele frequency of 0.25. Another strength was the use of a replication cohort that
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confirmed the same direction of the association of the TNFSF4 and MAPKAPK2 SNPs with
IA risk in both the discovery and replication populations. In addition, this study included
a comprehensive functional analysis conducted in the HFGP cohort that consisted of cQTL
analysis after stimulation of whole blood, PBMCs, and MDMs with A. fumigatus conidia
but also a comprehensive analysis of serological and plasmatic inflammatory biomarkers,
serum steroid hormones, and blood-derived immune cells. Functional experiments also
included assessment of fungicidal activity on human MDM infected with A. fumigatus,
which allowed us to directly measure the impact of TNFSF4 and MAPKAPK2 SNPs on the
efficiency of A. fumigatus clearance. Finally, a drawback was the multicenter nature of this
study that placed inevitable limitations in clinical data collection that made impossible, for
instance, the adjustment of the genetic association analysis for antifungal prophylaxis.
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